|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
16 December 2017 |
|
Main ID: |
NCT02747472 |
|
Date of registration:
|
19/04/2016 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
GIP Receptor Antagonist Studies in Humans
GA-1 |
|
Scientific title:
|
Involvement of Glucose-dependent Insulinotropic Polypeptide (GIP) in Human Physiology and Pathophysiology - Receptor Antagonist Studies in Humans |
|
Date of first enrolment:
|
April 2016 |
|
Target sample size:
|
10 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT02747472 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Basic Science. Masking: Triple (Participant, Investigator, Outcomes Assessor).
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
Denmark
| | | | | | | |
|
Contacts
|
|
Name:
|
Filip K Knop, MD, PhD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
UHGentofte, Center for Diabetes Research |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Normal kidney function, liver function and hemoglobin levels.
Exclusion Criteria:
- Medication, Diabetes type 1 or 2, BMI > 25, first degree relatives with Type 2
Diabetes
Age minimum:
20 Years
Age maximum:
30 Years
Gender:
Male
|
|
Health Condition(s) or Problem(s) studied
|
|
Glucose Metabolism
|
|
Intervention(s)
|
|
Drug: GIP(1-42)
|
|
Drug: GIP-A
|
|
Other: Saline
|
|
Primary Outcome(s)
|
|
Insulin levels
[Time Frame: 65 minutes]
|
|
Secondary ID(s)
|
|
UHG-CFD-GIPANTA-1
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|